These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1678919)

  • 1. Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
    Strom JA; Zola B; Frishman W; Laddu A; Wexler JP; Carlson K; Jordan A
    Am Heart J; 1991 Sep; 122(3 Pt 2):892-900. PubMed ID: 1678919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs.
    Sharma R; Ahuja VM; Fahim M
    Indian J Exp Biol; 2004 Dec; 42(12):1195-9. PubMed ID: 15623230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
    Leier CV; Patterson SE; Huss P; Parrish D; Unverferth DV
    Am J Med Sci; 1986 Sep; 292(3):128-35. PubMed ID: 2875651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic recovery during simulated ventricular tachycardia: role of adrenergic receptor activation.
    Feldman T; Carroll JD; Munkenbeck F; Alibali P; Feldman M; Coggins DL; Gray KR; Bump T
    Am Heart J; 1988 Mar; 115(3):576-87. PubMed ID: 2894148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report.
    Cohen A
    Am J Med; 1986 May; 80(5B):86-93. PubMed ID: 2872814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
    Deger G
    Am J Med; 1986 May; 80(5B):62-7. PubMed ID: 2872809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension.
    Cardillo C; Degen C; Campia U; De Felice F; Folli G
    J Clin Pharmacol; 1993 May; 33(5):433-8. PubMed ID: 8101194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
    Starling MR
    Am Heart J; 1994 Jul; 128(1):124-33. PubMed ID: 8017265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
    Yasumoto K; Takata M; Yoshida K; Mikawa M; Tomoda F; Sasayama S
    J Hum Hypertens; 1990 Feb; 4(1):13-8. PubMed ID: 1971654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
    Magorien RD; Sinnathamby S; Leier CV; Boudoulas H; Unverferth DV
    Am J Cardiol; 1990 Mar; 65(9):638-43. PubMed ID: 1968703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of intravenous metoprolol.
    Bourdillon PD; Canepa-Anson R; Rickards AF
    Am J Cardiol; 1979 Nov; 44(6):1195-200. PubMed ID: 495515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of terazosin.
    Kyncl JJ
    Am J Med; 1986 May; 80(5B):12-9. PubMed ID: 2872801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of terazosin in congestive heart failure.
    Zhu J; Wang D; Lu Z; Liu Z; Yang D
    Chin Med Sci J; 1993 Jun; 8(2):98-100. PubMed ID: 7904837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with terazosin administered in combination with other antihypertensive agents.
    Chrysant SG
    Am J Med; 1986 May; 80(5B):55-61. PubMed ID: 2872808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flosequinan: a vasodilator with positive inotropic activity.
    Corin WJ; Monrad ES; Strom JA; Giustino S; Sonnenblick ES; LeJemtel T
    Am Heart J; 1991 Feb; 121(2 Pt 1):537-40. PubMed ID: 1990760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension.
    Albillos A; Lledó JL; Bañares R; Rossi I; Iborra J; Calleja JL; Garrido A; Escartin P; Bosch J
    Hepatology; 1994 Sep; 20(3):611-7. PubMed ID: 7915703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.